文献速递血栓与止血

低剂量阿司匹林与安慰剂用于产后静脉血栓栓塞症:一项多国、先导性、随机、安慰剂对照试验

Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Haematol · 2025-01-16

PARTUM先导试验在加拿大、法国、爱尔兰和荷兰七家中心纳入产后具备≥2项静脉血栓栓塞症危险因素或轻中度易栓症且年龄≥18岁者,于分娩后48小时内按1:1随机分配至低剂量阿司匹林组(81 mg,欧洲80 mg)或安慰剂组口服每日一次共42天,主要结局为月均每中心招募率6.3(95%CI 5.5-7.2)例,低剂量阿司匹林组无静脉血栓栓塞症事件而安慰剂组1例发生远端深静脉血栓,无大出血,作者认为开展全球产后血栓预防试验可行且有必要。

要点

  • 产后具备≥2项静脉血栓栓塞症危险因素或轻中度易栓症者中,低剂量阿司匹林组无静脉血栓栓塞症事件,安慰剂组1例发生远端深静脉血栓。
  • 低剂量阿司匹林组3例(2%)与安慰剂组1例(1%)发生临床相关非大出血,绝对风险差1.66(95%CI -1.54至4.86)。
  • 257例参与者中9例(4%)发生10起严重不良事件,271名婴儿中10名(4%)发生11起严重不良事件,无治疗相关死亡。

核心结论

  • 作者认为开展评估低剂量阿司匹林的全球产后血栓预防试验可行且有必要,以提供高质量数据。

研究设计与样本

  • PARTUM为多国、随机、双盲、安慰剂对照先导试验,在加拿大、法国、爱尔兰和荷兰七家中心开展。
  • 产后年龄≥18岁且具备静脉血栓栓塞症危险因素(包括轻中度遗传性易栓症、产前制动、孕前BMI≥30 kg/m2、孕前吸烟、既往浅静脉血栓及其他妊娠相关情况)者纳入。
  • 参与者于分娩后48小时内按1:1随机分配至低剂量阿司匹林组(81 mg,欧洲80 mg)口服每日一次或安慰剂组口服每日一次,共42天,产后6周和90天随访。
  • 主要结局为月均每中心招募率,其他可行性指标及临床结局按意向性治疗分析。
  • 2020年11月2日至2023年6月19日评估10040例,808例符合全部入选标准,257例(32%)签署知情同意并入组,低剂量阿司匹林组127例、安慰剂组130例。

主要发现

  • 中位随访91天(IQR 89-96),中位年龄34.0岁(IQR 30.0-37.0),161例(63%)为白人。
  • 月均每中心招募率为6.3(95%CI 5.5-7.2)例。
  • 低剂量阿司匹林组无静脉血栓栓塞症事件,安慰剂组1例发生远端深静脉血栓(-0.82,95%CI -2.42至0.78)。
  • 无大出血发生;低剂量阿司匹林组3例(2%)与安慰剂组1例(1%)发生临床相关非大出血,绝对风险差1.66(95%CI -1.54至4.86)。
  • 257例参与者中9例(4%)发生10起严重不良事件,271名婴儿中10名(4%)发生11起严重不良事件,无治疗相关死亡。

临床怎么用

  • 作者认为开展评估低剂量阿司匹林的全球产后血栓预防试验可行且有必要,以提供高质量数据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the morbidity and mortality of venous thromboembolism, there is little evidence to guide postpartum thromboprophylaxis in patients at moderate risk. We aimed to assess the feasibility of conducting a double-blind, randomised trial of aspirin versus placebo in postpartum individuals with two or more venous thromboembolism risk factors, mild-to-moderate thrombophilia, or both. METHODS: The pilot PARTUM trial, a multi-national, randomised, double-blind, placebo-controlled trial, was conducted in seven centres across Canada, France, Ireland, and the Netherlands. Postpartum individuals aged 18 years or older with venous thromboembolism risk factors, including mild-moderate inherited thrombophilia, antepartum immobilisation, pre-pregnancy BMI of 30 kg/m2 or higher, pre-pregnancy smoking, previous superficial vein thrombosis, and other pregnancy-related conditions, were eligible. Participants were randomly assigned (1:1) within 48 h of delivery to aspirin 81 mg (80 mg in Europe) orally daily (low-dose aspirin group) or placebo orally once daily (placebo group) for 42 days. Follow-up visits occurred at 6 weeks and 90 days postpartum. The primary outcome was the mean recruitment rate (participants per site per month). Additional feasibility metrics were reported, and clinical outcomes were analysed by intention to treat. This study is registered with ClinicalTrials.gov, NCT04153760, and EudraCT, 2020-000619-58, and is completed. FINDINGS: Between Nov 2, 2020, and June 19, 2023, 10 040 patients were assessed for eligibility and 808 met all eligibility criteria, of whom 257 (32%) provided consent and were enrolled. 127 were randomly assigned to the low-dose aspirin group and 130 to the placebo group. The median follow-up was 91 days (IQR 89-96). The median age was 34·0 years (IQR 30·0-37·0), and 161 (63%) of participants were White. The mean recruitment rate was 6·3 (95% CI 5·5 to 7·2) patients per site per month. No venous thromboembolism events occurred in the low-dose aspirin group, and one participant had distal deep vein thrombosis in the placebo group (-0·82 [95% CI -2·42 to 0·78]). No major bleeds occurred. Three (2%) participants in the low-dose aspirin group versus one (1%) in the placebo group had clinically relevant non-major bleeds (absolute risk difference 1·66 [95% CI -1·54 to 4·86]). Ten serious adverse events occurred in nine (4%) of 257 participants, and 11 serious adverse events occurred in ten (4%) of 271 infants of participants. No treatment-related death occurred. INTERPRETATION: A global postpartum thromboprophylaxis trial evaluating low-dose aspirin is possible and needed to provide high-quality data. FUNDING: Canadian Institutes of Health Research and the INVENT-VTE Network.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Skeith L, Malinowski AK, El-Chaâr D, et al. Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial. Lancet Haematol. 2025. PMID: 39827892. doi:10.1016/S2352-3026(24)00338-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。